Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective of the Spanish National Health System. Analyse...

Full description

Bibliographic Details
Main Authors: Antonio Olry de Labry Lima, Zuzana Špacírová, Silvia Fénix-Caballero, Antonio Matas Hoces, Adrián Sánchez Vegas, Manuel Cárdenas Aranzana, Jesús F. Sierra-Sánchez, María del Carmen Martínez Díaz, Emilio Jesús Alegre del Rey
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Breast
Subjects:
Breast neoplasms
Healthcare costs
Poly(ADP-Ribose) polymerase inhibitors
Cost-utility analysis
Progression-free survival
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621003568

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621003568

Similar Items